 Fulcrum Therapeutics, Inc. FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2020. Despite these unprecedented times, the first quarter was a period of important progress for Fulcrum and the fundamentals of our business remain strong, said Robert J. Gould, Ph.D., president and chief executive officer. In the wake of COVID-19, a number of our clinical trial sites postponed their activities. 